Does the media prefer ABVX or IOVA?

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Abivax. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 1 mentions for Abivax. Abivax's average media sentiment score of 1.76 beat Iovance Biotherapeutics' score of 0.63 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Iovance Biotherapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IOVA or KRYS?

In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 11 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.81 beat Iovance Biotherapeutics' score of 0.63 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NUVL or IOVA?

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 1 mentions for Nuvalent. Iovance Biotherapeutics' average media sentiment score of 0.63 beat Nuvalent's score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or IOVA?

In the previous week, Iovance Biotherapeutics had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 8 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.99 beat Iovance Biotherapeutics' score of 0.63 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Iovance Biotherapeutics (IOVA) Competitors

$8.99 +1.00 (+12.52%)

Closing price 04:00 PM Eastern

Extended Trading

$8.95 -0.04 (-0.44%)

As of 06:46 PM Eastern

Compare

IOVA vs. ABVX, PRAX, KRYS, NUVL, and PTGX

Should you buy Iovance Biotherapeutics stock or one of its competitors? Iovance Biotherapeutics's main competitors and comparable companies include Abivax (ABVX), Praxis Precision Medicines (PRAX), Krystal Biotech (KRYS), Nuvalent (NUVL), and Protagonist Therapeutics (PTGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Iovance Biotherapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Abivax currently has a consensus price target of $156.50, indicating a potential upside of 32.41%. Iovance Biotherapeutics has a consensus price target of $8.75, indicating a potential downside of 2.67%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts clearly believe Abivax is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Abivax has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.51% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Abivax. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 1 mentions for Abivax. Abivax's average media sentiment score of 1.76 beat Iovance Biotherapeutics' score of 0.63 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Iovance Biotherapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Abivax has higher earnings, but lower revenue than Iovance Biotherapeutics. Abivax is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Iovance Biotherapeutics	$263.50M	15.45	-$390.98M	-$0.73	N/A

Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

Summary

Iovance Biotherapeutics beats Abivax on 8 of the 15 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Praxis Precision Medicines has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Praxis Precision Medicines' return on equity of -34.15% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

In the previous week, Iovance Biotherapeutics had 7 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 5 mentions for Praxis Precision Medicines. Iovance Biotherapeutics' average media sentiment score of 0.63 beat Praxis Precision Medicines' score of 0.52 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines has higher earnings, but lower revenue than Iovance Biotherapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,190.53	-$303.27M	-$12.93	N/A
Iovance Biotherapeutics	$263.50M	15.45	-$390.98M	-$0.73	N/A

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Praxis Precision Medicines presently has a consensus target price of $579.55, indicating a potential upside of 58.96%. Iovance Biotherapeutics has a consensus target price of $8.75, indicating a potential downside of 2.67%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities research analysts clearly believe Praxis Precision Medicines is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Praxis Precision Medicines has a beta of 2.78, indicating that its stock price is 178% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Summary

Praxis Precision Medicines beats Iovance Biotherapeutics on 9 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Krystal Biotech?

Iovance Biotherapeutics (NASDAQ:IOVA) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Iovance Biotherapeutics presently has a consensus price target of $8.75, indicating a potential downside of 2.67%. Krystal Biotech has a consensus price target of $365.40, indicating a potential upside of 8.42%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Krystal Biotech has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	15.45	-$390.98M	-$0.73	N/A
Krystal Biotech	$440.48M	22.65	$204.83M	$7.98	42.23

In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 11 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.81 beat Iovance Biotherapeutics' score of 0.63 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a net margin of 54.82% compared to Iovance Biotherapeutics' net margin of -89.11%. Krystal Biotech's return on equity of 19.34% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Krystal Biotech	54.82%	19.34%	17.65%

Iovance Biotherapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Krystal Biotech beats Iovance Biotherapeutics on 15 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Iovance Biotherapeutics (NASDAQ:IOVA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 1 mentions for Nuvalent. Iovance Biotherapeutics' average media sentiment score of 0.63 beat Nuvalent's score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Nuvalent's return on equity of -40.11% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Iovance Biotherapeutics has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Iovance Biotherapeutics	$263.50M	15.45	-$390.98M	-$0.73	N/A

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nuvalent currently has a consensus price target of $127.73, indicating a potential upside of 3.04%. Iovance Biotherapeutics has a consensus price target of $8.75, indicating a potential downside of 2.67%. Given Nuvalent's higher probable upside, analysts clearly believe Nuvalent is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Nuvalent has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Summary

Iovance Biotherapeutics beats Nuvalent on 10 of the 15 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Iovance Biotherapeutics had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 8 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.99 beat Iovance Biotherapeutics' score of 0.63 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has a net margin of 29.40% compared to Iovance Biotherapeutics' net margin of -89.11%. Protagonist Therapeutics' return on equity of 12.03% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Protagonist Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	211.89	-$130.15M	$1.03	146.30
Iovance Biotherapeutics	$263.50M	15.45	-$390.98M	-$0.73	N/A

Protagonist Therapeutics presently has a consensus target price of $140.53, suggesting a potential downside of 6.74%. Iovance Biotherapeutics has a consensus target price of $8.75, suggesting a potential downside of 2.67%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Protagonist Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

Summary

Protagonist Therapeutics beats Iovance Biotherapeutics on 13 of the 17 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IOVA vs. The Competition

Export

Metric	Iovance Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.62B	$4.07B	$7.37B	$12.86B
Dividend Yield	N/A	3.64%	2.53%	10.69%
P/E Ratio	-12.31	11.53	268.43	24.05
Price / Sales	15.45	1,348.34	621.48	93.85
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	5.55	17.09	13.07	6.15
Net Income	-$390.98M	-$12.52M	$3.46B	$347.39M
7 Day Performance	37.88%	2.74%	1.43%	-0.64%
1 Month Performance	79.08%	6.15%	4.58%	2.12%
1 Year Performance	255.34%	60.36%	27.60%	20.16%

Iovance Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IOVA Iovance Biotherapeutics	1.4486 of 5 stars	$8.99 +12.5%	$8.75 -2.7%	+207.3%	$3.62B	$263.50M	N/A	500	News Coverage Analyst Forecast High Trading Volume
ABVX Abivax	2.4803 of 5 stars	$127.50 -2.6%	$156.50 +22.7%	+74.8%	$11.12B	N/A	N/A	61	Positive News
PRAX Praxis Precision Medicines	3.0072 of 5 stars	$366.96 +1.7%	$573.05 +56.2%	+762.2%	$10.25B	$8.55M	N/A	110	Analyst Forecast
KRYS Krystal Biotech	4.1999 of 5 stars	$331.59 +1.6%	$361.56 +9.0%	+138.5%	$9.82B	$389.13M	41.55	210	Analyst Downgrade
NUVL Nuvalent	1.7222 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IOVA) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. ABVX, PRAX, KRYS, NUVL, and PTGX

How does Iovance Biotherapeutics compare to Abivax?

Summary

How does Iovance Biotherapeutics compare to Praxis Precision Medicines?

Summary

How does Iovance Biotherapeutics compare to Krystal Biotech?

Summary

How does Iovance Biotherapeutics compare to Nuvalent?

Summary

How does Iovance Biotherapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. ABVX, PRAX, KRYS, NUVL, and PTGX

How does Iovance Biotherapeutics compare to Abivax?

Do analysts prefer ABVX or IOVA?

Is ABVX or IOVA more profitable?

Does the media prefer ABVX or IOVA?

Do institutionals and insiders have more ownership in ABVX or IOVA?

Which has preferable valuation and earnings, ABVX or IOVA?

Which has more risk & volatility, ABVX or IOVA?

Summary

How does Iovance Biotherapeutics compare to Praxis Precision Medicines?

Is PRAX or IOVA more profitable?

Does the media prefer PRAX or IOVA?

Which has preferable earnings and valuation, PRAX or IOVA?

Do institutionals & insiders believe in PRAX or IOVA?

Do analysts recommend PRAX or IOVA?

Which has more volatility and risk, PRAX or IOVA?

Summary

How does Iovance Biotherapeutics compare to Krystal Biotech?

Do analysts prefer IOVA or KRYS?

Which has preferable earnings & valuation, IOVA or KRYS?

Does the media refer more to IOVA or KRYS?

Is IOVA or KRYS more profitable?

Which has more volatility and risk, IOVA or KRYS?

Do institutionals and insiders believe in IOVA or KRYS?

Summary

How does Iovance Biotherapeutics compare to Nuvalent?

Does the media favor NUVL or IOVA?

Is NUVL or IOVA more profitable?

Which has higher valuation & earnings, NUVL or IOVA?

Do insiders & institutionals believe in NUVL or IOVA?

Do analysts recommend NUVL or IOVA?

Which has more risk & volatility, NUVL or IOVA?

Summary

How does Iovance Biotherapeutics compare to Protagonist Therapeutics?

Does the media prefer PTGX or IOVA?

Is PTGX or IOVA more profitable?

Which has higher valuation & earnings, PTGX or IOVA?

Do analysts rate PTGX or IOVA?

Do institutionals and insiders hold more shares of PTGX or IOVA?

Which has more risk and volatility, PTGX or IOVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools